Skip to main content

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by Rheu

Social Author Name
Dr. John Cush
Tweet Content
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

RT @RichardPAConway: Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commeric

Social Author Name
Richard Conway
Tweet Content
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa

RT @AkhilSoodMD: Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer - % serious infe

Social Author Name
Akhil Sood MD
Tweet Content
Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer - % serious infection in TNFi in high vs low placental transfer (2.1% vs 1.6%) - HR (high vs low) 0.98 (95% CI 0.36-2.61) - No significant difference in risk of serious infxn @RheumNow #ACR22 https://t.co/7Lfpf7PERu

RT @DrCassySims: Which patients with IIM are high risk for #cancer? Abstract #0002 #ACR22 @RheumNow #ACRBest 📍Der

Social Author Name
Catherine Sims, MD
Tweet Content
Which patients with IIM are high risk for #cancer? Abstract #0002 #ACR22 @RheumNow #ACRBest 📍Dermatomyositis 📍Anti-TIF-gamma, anti-NXP2 📍Age > 40y at dz onset 📍Dysphagia 📍Cutaneous necrosis 📍Persistent high dz despite immunosuppressive tx

RT @drdavidliew: Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT sur

Social Author Name
David Liew
Tweet Content
Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsiveness👀) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD

RT @synovialjoints: Vaccination +/- prior Covid-19, and with either mRNA or vectored DNA vaccines were not associated wi

Social Author Name
Dr. Antoni Chan
Tweet Content
Vaccination +/- prior Covid-19, and with either mRNA or vectored DNA vaccines were not associated with AIRD flares. Negative association 21-days after 1st Covid-19 vaccination and no association after 2nd or 3rd doses. Nakafero G Abs#2194 https://t.co/vA8cMNQGkr #ACR22 @RheumNow https://t.co/SZnXejnmYt

RT @RichardPAConway: Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR

Social Author Name
Richard Conway
Tweet Content
Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR 1.34, any infection aHR 1.18, hospitalisation aHR 1.34 (all relative non-frail). @RheumNow #ACR22 Abstr#2218 https://t.co/ONsTBq8ehB https://t.co/iTVANh5flk

RT @ericdeinmd: Thieves Market #ACR22 Ulcerative palatal lesions, non-spec bx +ANA 1:320 w other neg Abs Empiric steroid

Social Author Name
Eric Dein
Tweet Content
Thieves Market #ACR22 Ulcerative palatal lesions, non-spec bx +ANA 1:320 w other neg Abs Empiric steroids for presumed vasculitis New cavitary lung lesion. Pathology showed vasculitis Dacrocystitis w lobulated paranasal mass Dx: Extra nodal NK/T-cell lymphoma Fatal case @RheumNow https://t.co/TlDy9GfW7N

RT @RichardPAConway: Flatman et al. Risk of infections in children with third trimester TNFi use, high vs low (CTZ, ETN)

Social Author Name
Richard Conway
Tweet Content
Flatman et al. Risk of infections in children with third trimester TNFi use, high vs low (CTZ, ETN) placental transfer. No difference but wide CIs, aHR 0.98 (0.36, 2.61) @RheumNow #ACR22 Abstr#2192 https://t.co/350UxX9bkL https://t.co/29uOtek8w7

RT @AurelieRheumo: 💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insom

Social Author Name
Aurelie Najm
Tweet Content
💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insomnia Severity Index -9.8 RAID -1.4 PGA -13 Small sample size wk6 trend improvement sleep efficiency 89% vs84% p=0.07 but not wk26 https://t.co/rpKdtbREYs Abs#2188 #ACR22 @RheumNow https://t.co/kEBcPAdIKW
Subscribe to
×